MORE TO EXPLORE
Get expert insights and real-world perspectives from leading voices in the industry to help you make more informed decisions.
The Broker Innovation Lab celebrates brokers and other benefits stakeholders who have embraced the changing marketplace to position themselves and their business for future success
Media & Resources
With pharmacy benefits accounting for 21 cents of every health care dollar, prescription drugs are the most expensive health care benefit component. Some of those drugs are more expensive than others—a lot more expensive, as a just-released report reveals. For two years, telemedicine platform and prescription drug price tracker GoodRx has been keeping tabs on the priciest prescription drugs. Their 2020 list shows that while most of the drugs have remained the same price since last year, there are some notable changes. Daraprim, which sparked a national conversation about drug prices during the Martin Shkreli trial, is no longer on the list now that there's finally a generic on the market. Discontinued drugs Kynmaro and Viekira XR have also been removed from the list. Related: FDA approves $2.1 million gene therapy drug The only newly approved drug on the list is Qinlock, which treats gastrointestinal stromal tumor (GIST). Other new additions to the list include Korlym and Cerdelga. Qinlock ranks 14th on the list, with a list price above $30,000 a month. Cerdelga and Korlym rank 16th and 20th, respectively. GoodRx's list includes drugs that patients can get at a pharmacy and administer themselves, and is determined by tracking list price and dosing requirements. It does not include medications that must be administered by a healthcare practitioner. See our slideshow above for the top 10 most expensive drugs on the list, and click here for the full report. Read more:
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Sponsored by Garner Health
The Biologic Problem: Employers Are Paying for a Brand, Not a Breakthrough
